Introduction {#jcmm13051-sec-0001}
============

Acquired genetic alterations in *RUNX1* are frequently associated with numerous myeloid malignancies, especially acute myeloid leukaemia (AML) (40% of FAB M0 immature AMLs [1](#jcmm13051-bib-0001){ref-type="ref"}) and more rarely with T cell acute lymphoblastic leukaemia (T‐ALL) (25% of early thymic immature T‐ALL (ETP‐ALL) [2](#jcmm13051-bib-0002){ref-type="ref"}).

Germline *RUNX1* mutations are found in FPD/AML characterized by thrombocytopaenia, and a 35% life‐time risk of developing myelodysplastic syndrome (MDS) and/or AML. [3](#jcmm13051-bib-0003){ref-type="ref"} T‐ALL development has also been reported in rare cases [4](#jcmm13051-bib-0004){ref-type="ref"}, [5](#jcmm13051-bib-0005){ref-type="ref"}. In AML, contrary to T‐ALL, the leukaemic transformation is almost always associated with a somatic *RUNX1* mutation on the second allele [4](#jcmm13051-bib-0004){ref-type="ref"}, [6](#jcmm13051-bib-0006){ref-type="ref"}, [7](#jcmm13051-bib-0007){ref-type="ref"}. Acquired mutations in *CDC25C* and *GATA2* have also been identified at a high frequency but only in a Japanese cohort [4](#jcmm13051-bib-0004){ref-type="ref"}, [7](#jcmm13051-bib-0007){ref-type="ref"}, [8](#jcmm13051-bib-0008){ref-type="ref"}, [9](#jcmm13051-bib-0009){ref-type="ref"}, suggesting that environmental and/or ethnic factors may play an important role in leukaemia transformation. Somatic mutations in *FLT3*,*PHF6*,*KIT*,*KRAS*,*RAD21*,*BCOR*,*BCORL1*,*CBL*,*CEBPA*,*MPL*,*TP53*,*WT1*,*SRSF2*,*DNMT3A*,*TET2* and *ASXL1* were described in patients who developed AML/MDS and mutations in *PHF6*,*WT1*,*NOTCH1*,*FLT3* and *ASXL1* in patients with T‐ALL [4](#jcmm13051-bib-0004){ref-type="ref"}, [5](#jcmm13051-bib-0005){ref-type="ref"}, [7](#jcmm13051-bib-0007){ref-type="ref"}, [9](#jcmm13051-bib-0009){ref-type="ref"}.

Materials and methods {#jcmm13051-sec-0002}
=====================

Patient samples {#jcmm13051-sec-0003}
---------------

Biologic samples of one FPD/AML pedigree were collected between 2006 and 2013 after informed consent, in accordance with the Declaration of Helsinki. Genomic DNA was extracted from fibroblasts, CD34^+^ cells, peripheral blood mononuclear and bone marrow total cells using kit Qiagen (Les Ulis, France).

CGH arrays {#jcmm13051-sec-0004}
----------

Comparative genomic hybridization (CGH) arrays were performed on human CGH 2x400K (G4448A) (Agilent, Les Ulis, France) by hybridization of sample *versus* normal‐matched commercial reference. CGH data and protocols have been submitted to ArrayExpress at the EBI with the accession number E‐MTAB‐4623.

Exome capture and sequencing (v4+UTR, 70 Mb) {#jcmm13051-sec-0005}
--------------------------------------------

Library preparation, capture, sequencing and variant detection have been carried out by IntegraGen. Exons were captured from blood DNA using Agilent SureSelect Human All Exon v5--70 Mb kit and sequenced on IlluminaHiSEQ 2000 instrument as previously described [10](#jcmm13051-bib-0010){ref-type="ref"}. WES data and prodtocols have been submitted to ArrayExpress at the European Bioinformatics Institute (EBI) with the accession number E‐MTAB‐4679. Variants present in the internal control and in public databases at a frequency of \>1% were excluded, and only non‐synonymous mutations predicted by PolyPhen2 to be probably or possibly deleterious were analysed.

Targeted NGS {#jcmm13051-sec-0006}
------------

The mutated regions were amplified by PCR using primers listed in Table S1. PCR products were end‐repaired, extended with an 'A' base on the 3′ end, ligated with indexed paired‐end adaptors (NEXTflex, Bioo Scientific, Saint Marcel, France) using the Bravo Platform (Agilent) and amplified by PCR for four cycles. Amplicon libraries were sequenced in an IlluminaMiSeq flow cell using the onboard cluster method, as paired‐end sequencing (2 × 250 bp reads) (Illumina, San Diego, CA, USA).

Results {#jcmm13051-sec-0007}
=======

We focus on a man with a familial history of *RUNX1* ^R174Q^ mutation, previously referenced as AII‐1 [11](#jcmm13051-bib-0011){ref-type="ref"}, [12](#jcmm13051-bib-0012){ref-type="ref"}, who developed at the age of 42 years an EGIL (European Group of Immunological Characterization of Leukemia) T2‐ALL with a loss of the 1p36 and 17q12 regions and the *ASXL1* ^R693^\* mutation in the leukaemic clone. The patient was pre‐treated with corticosteroids and then treated according to the French GRAALL2003 protocol based on a polychemotherapy [13](#jcmm13051-bib-0013){ref-type="ref"}. As 15 days later the blasts were still present in the bone marrow, a second induction course with idarubicin and cytarabine was performed. The patient achieved complete remission [5](#jcmm13051-bib-0005){ref-type="ref"}.

Two years later, he was admitted to the hospital for relapse with 87% blasts in peripheral blood. The clinical course was aggressive and the patient died 1 month after hospitalization. The blasts exhibited basophilic cytoplasm and a lack of azurophilic granules (Figure S1A) and were characterized by immature marker expression (CD34^+^, CD13^+^, HLA‐DR^+^, CD33^low^, CD7^+^ and CD56^low^) and absence of cytoplasmic and surface expression of CD3 and cyMPO (Figure S1B, C). This phenotype was initially described by Suzuki as myeloid/NK‐cell precursor leukaemia [14](#jcmm13051-bib-0014){ref-type="ref"} and represents a distinct subtype of AML‐M0 [15](#jcmm13051-bib-0015){ref-type="ref"}. In contrast to previously described cases, we detected low expression of TdT, CD10, CD19, cyCD79a and CD5 (Figure S1B, C).

To investigate whether initial (T2‐ALL) and relapsed (AML‐M0) leukaemic blasts originated from the same clone, we performed first aCGH on both blast populations. In both samples, aCGH revealed loss of 1p36.32‐23 and of 17q11.2 and other small deletions (Table S2). One additional deletion on chromosome 11 and five duplicated regions on chromosome 14 were found exclusively in T2‐ALL (Table S2). In the AML‐M0 blasts, the loss of the 1p36.32‐23 region was associated with two large amplifications at the same break point (1p36.33‐32 and 1p36.23‐1p31.2) surrounding the deleted region (Figure S2). Other additional deletions and duplications were identified (Table S2). These results suggested that T2‐ALL and AML‐M0 blasts originated from the same clone, but harboured also specific features acquired during disease progression. Furthermore, identical clonal rearrangements of TCRγ (Vγ9‐Jγ1.1) and TCRδ (Dδ2‐Jδ1 and Dδ2‐Jδ3) (Figure S3 and data not shown) were identified in both T2‐ALL and AML‐M0 blasts strongly supporting their clonal affiliation. Finally, analysis of WES revealed 34 variants in the T2‐ALL and 49 in the AML‐M0. Interestingly, 20 variants were common between these two cell populations (Table [1](#jcmm13051-tbl-0001){ref-type="table-wrap"}). Taking into consideration that T2‐ALL blasts represented about 58% of the sequenced DNA and AML‐M0 blasts 87%, 18 genes were found to be mutated in the original clone at a frequency of more than 40% (or about 100% for X‐linked genes) (Table [1](#jcmm13051-tbl-0001){ref-type="table-wrap"}), suggesting that they were all present as heterozygous mutations. The results were confirmed by NGS (Table S3). Alterations in genes frequently associated with myeloid and/or lymphoid malignancies, such as *PHF6*,*EZH2*,*ASXL1*,*JAK1*,*JAK3*,*TET2* and *NOTCH1*, were found. We also identified nine probably deleterious (*CXCR4, IRS4, HCFC1, CTNND2, NRF1, PTPN13, PPP2R2B, MSRB2* and *MYO1D*) and two possibly deleterious *de novo* variants (*EPHA10, PCNXL2*) in genes that were also found with a frequency of \>40% but had not previously been causally linked to AML/MDS. A second heterozygous *NOTCH1* ^K1488N^ mutation occurred only in the T2‐ALL (Table [2](#jcmm13051-tbl-0002){ref-type="table-wrap"}), while the initial *NOTCH1* ^K1607delinsNAK^ mutation became homozygous in AML‐M0 (Table [1](#jcmm13051-tbl-0001){ref-type="table-wrap"}). PRB4 mutated with an approximate 40% frequency only in T2‐ALL could be a passenger mutation. In the AML‐M0, only one variant was present at 50% but absent in T2‐ALL, *SUDS3* ^R325H^ (Table [3](#jcmm13051-tbl-0003){ref-type="table-wrap"}). SUDS3 is a subunit of the histone deacetylase‐dependent SIN3A corepressor complex interacting with RUNX1 and its genetic alterations could lead to a deregulation of RUNX1 transcriptional program. No acquired *RUNX1* mutation was found in T2‐ALL and AML‐M0.

###### 

Gene mutations common to both T2‐ALL and AML‐M0

  Gene, chr          Protein                                              Variant frequency in T2‐ALL (%)   Variant frequency in AML‐M0 (%)
  ------------------ ---------------------------------------------------- --------------------------------- --------------------------------------------
  PHF6, chrX         S247Y                                                63                                96
  IRS4, chrX         G1154V                                               49                                92
  HCFC1, chrX        R1982H                                               55                                89
  CXCR4, chr2        V116Afs[\*](#jcmm13051-note-0004){ref-type="fn"}55   36                                80
  EZH2, chr7         S669N                                                34                                44
  EPHA10, chr1       R268H                                                30                                29[†](#jcmm13051-note-0004){ref-type="fn"}
  CTNND2, chr5       R82[\*](#jcmm13051-note-0004){ref-type="fn"}         28                                48
  NRF1, chr7         R206W                                                27                                50
  ASXL1, chr20       R693[\*](#jcmm13051-note-0004){ref-type="fn"}        27                                52
  PTPN13, chr4       R1838Q                                               25                                47
  PPP2R2B, chr5      K363Q                                                25                                51
  JAK1, chr1         R879H                                                24                                54
  JAK3, chr19        R657Q                                                21                                55
  TET2, chr4         P1962T                                               23                                47
  MSRB2, chr10       T59I                                                 23                                42
  PCNXL2, chr1       R1169W                                               21                                52[†](#jcmm13051-note-0004){ref-type="fn"}
  MYO1D, chr17       R560Q                                                21                                48
  **NOTCH1, chr9**   **K1607delinsNLQ**                                   **29**                            **97**
  OPRD1, chr1        I279N                                                18                                36
  RRP7A, chr22       F241del                                              11                                20

\*stop codon, ^†^possibly damaging, in bold: mutation present at heterozygous state in T2‐ALL and at homozygous state in AML‐M0.

John Wiley & Sons, Ltd

###### 

Genes mutated only in T2‐ALL

  Gene, chr          Protein                                                   Variant frequency in T2‐ALL (%)
  ------------------ --------------------------------------------------------- --------------------------------------------
  NOTCH1‐bis, chr9   K1488N                                                    20
  PRB4, chr12        G164R                                                     20
  ITGAX, chr16       D810Y                                                     19
  AQP5, chr12        L74M                                                      14[†](#jcmm13051-note-0005){ref-type="fn"}
  GRIN3B, chr19      L824M                                                     14
  CUBN, chr10        A2914S                                                    13
  OBSCN, chr1        A8630E                                                    12
  SCARF2, chr22      R147S                                                     12
  DDX3X, chrX        G11W                                                      12
  PDZD2, chr5        L34I                                                      11
  MCM3, chr6         A461D                                                     11
  WNT3, chr17        R60S                                                      11
  ZIK1, chr19        A364delinsVLYF[\*](#jcmm13051-note-0005){ref-type="fn"}   11
  BCOR, chrX         L1203Sfs[\*](#jcmm13051-note-0005){ref-type="fn"}33       11

\*stop codon, ^†^possibly damaging, in bold: mutation present at heterozygous state in T2‐ALL and at homozygous state in AML‐M0.

John Wiley & Sons, Ltd

###### 

Genes mutated only in AML‐M0

  Gene, chr         Protein                                             Variant frequency in AML‐M0 (%)
  ----------------- --------------------------------------------------- ---------------------------------
  SUDS3, chr12      R325H                                               50
  SAP130, chr2      G803‐G804insPTQN                                    36
  GGT1, chr22       R107C                                               30
  LDB2, chr4        K355N                                               27
  ENPP2, chr8       V785M                                               26
  ATP8B1, chr18     R941G, G940V                                        23, 23
  LOC441155, chr6   A81T                                                22
  PVRIG, chr7       C62F                                                19
  MMEL1, chr1       P743H                                               18
  TMEM181, chr6     E111[\*](#jcmm13051-note-0006){ref-type="fn"}       18
  RBFOX3, chr17     E263[\*](#jcmm13051-note-0006){ref-type="fn"}       18
  GCGR, chr17       E362[\*](#jcmm13051-note-0006){ref-type="fn"}       18
  CENPC, chr4       E302[\*](#jcmm13051-note-0006){ref-type="fn"}       17
  PHACTR2, chr6     G201C                                               17
  MUC20, chr3       T447M                                               15
  FAM71F2, chr7     P198H                                               15
  WDR60, chr7       G1009C                                              15
  CSH2, chr17       V27I                                                15
  BAG6, chr6        P252T                                               14
  BCLAF1, chr6      S38Yfs[\*](#jcmm13051-note-0006){ref-type="fn"}38   14
  MYO9B, chr19      A1659S                                              14
  SLC17A7, chr19    R314S                                               14
  WDR52, chr3       E1818[\*](#jcmm13051-note-0006){ref-type="fn"}      12
  SOX7, chr8        P209T                                               12
  C19orf26, chr19   G349W                                               12
  MXRA5, chrX       E937[\*](#jcmm13051-note-0006){ref-type="fn"}       12
  SOBP, chr6        D569Y                                               11
  HSPA12B, chr20    R650S                                               11
  SUV39H1, chrX     C41[\*](#jcmm13051-note-0006){ref-type="fn"}        11

\*stop codon.

John Wiley & Sons, Ltd

To examine whether some of the potentially deleterious variants accumulated before leukaemia development, we screened 20 variants found with a high penetrance in both T2‐ALL and AML‐M0 clones by NGS on CD34^+^ cells obtained from the patient\'s peripheral blood 5 years prior to T2‐ALL development. The only somatic mutation identified was a *TET2* ^P1962T^ at a frequency of 1% (Table S3) reaching more than 40% at leukaemic stages. These results suggest that a missense *TET2* ^P1962T^ mutation in association with germline *RUNX1* ^R174Q^ mutation led to amplification of an haematopoietic clone susceptible to acquire other transforming alterations (Fig. [1](#jcmm13051-fig-0001){ref-type="fig"}).

![Clonal evolution in FPD/AML patient carrying germline *RUNX1* ^R174Q^ mutation. The clonal evolution with the different mutations occurring at various stages of the disease (thrombocytopaenia, T2‐ALL,AML‐M0) is represented. Frequency of the variants is listed in the Tables [1](#jcmm13051-tbl-0001){ref-type="table-wrap"}, [3](#jcmm13051-tbl-0003){ref-type="table-wrap"}. The other deletions and amplifications are listed in Table S2.](JCMM-21-1237-g001){#jcmm13051-fig-0001}

Discussion {#jcmm13051-sec-0008}
==========

Here, we describe a unique case of one FPD/AML patient who developed first one T2‐ALL and less than 2 years later an AML‐M0. We show that these two leukaemic clones originate from the common subclone harbouring alterations in genes frequently mutated in both types of leukaemia. We cannot exclude that AML‐M0 was induced by the chemotherapy used for T2‐ALL treatment, as it involved anthracyclines and cyclophosphamide known to generate genomic instability. Interestingly, one of the variant *TET2* ^P1962T^ was present at a frequency of 1% in haematopoietic progenitors of this patient 5 years prior to T2‐ALL development. A missense *TET2* mutation at the same position (P1962L) has been described in AML [16](#jcmm13051-bib-0016){ref-type="ref"} and T‐lymphoblastic lymphoma [17](#jcmm13051-bib-0017){ref-type="ref"}, and the role of TET2 in the clonal haematopoiesis preceding transformation in FPD/AML has been recently reported in another case of FPD/AML [18](#jcmm13051-bib-0018){ref-type="ref"}. However, this is the first report of a TET2^P1962T^ mutation leading to the amplification of a leukaemic clone.

Our results suggest the following model of transformation: the germline *RUNX1* mutation induces both alteration in haematopoiesis (more particularly increasing cycling) and a genetic instability [11](#jcmm13051-bib-0011){ref-type="ref"}. The acquisition of a somatic *TET2* mutation enhances self‐renewal of haematopoietic stem/progenitor cells [17](#jcmm13051-bib-0017){ref-type="ref"}, [19](#jcmm13051-bib-0019){ref-type="ref"}, [20](#jcmm13051-bib-0020){ref-type="ref"}, leading to a clonal haematopoiesis. This is not a clonal haematopoiesis of undetermined potential (CHIP) in this germline context, but a true pre‐leukaemic state responsible for the emergence of progressively divergent haematological malignancies.

In conclusion, this report presents a FPD/AML patient with a germline *RUNX1* mutation and an acquired *TET2* mutation leading to clonal haematopoiesis. During a five‐year follow‐up, the haematopoietic clone acquired other genetic alterations including mutations in 18 genes. These subclonal alterations led first to T2‐ALL development, and later to a T/Myeloid phenotype with an AML‐M0 development (Fig. [1](#jcmm13051-fig-0001){ref-type="fig"}).

Clonal haematopoiesis in asymptomatic *RUNX1* carriers under the age of 50 years was already reported [9](#jcmm13051-bib-0009){ref-type="ref"} suggesting together with our results that the identification of clonal haematopoiesis before leukaemia development in FPD/AML patients could serve as a marker of pre‐leukaemic state. This finding might be helpful in patient care, especially if bone marrow transplantation is considered.
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**Figure S1** Morphology and phenotype of AML‐M0 blasts.

**Figure S2** Comparative genomic hybridization array on T2‐ALL and AML‐M0 blast populations.

**Figure S3** TCRδ and TCRγ rearrangement analysis.
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Click here for additional data file.

###### 

**Table S1** List of primers used for NGS.

**Table S2** Deletions and insertions found in AML‐M0 btasts and/or T2‐ALL blasts by CGH array.

**Table S3** Variants found in AML‐M0 blasts, T2‐ALL blasts and CD34+ cells by NGS.
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